Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.0555.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 954.00K | 2.06M | 771.00K | 987.00K | 1.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.50M | 5.48M | 3.12M | 2.99M | 3.95M |
| Operating Income | -3.50M | -5.48M | -3.12M | -2.99M | -3.95M |
| Income Before Tax | -3.45M | -5.18M | -2.60M | -3.10M | -4.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.45M | -5.18M | -2.60M | -3.10M | -4.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.45M | -5.18M | -2.60M | -3.10M | -4.14M |
| EBIT | -3.50M | -5.48M | -3.12M | -2.99M | -3.95M |
| EBITDA | -3.41M | -5.45M | -2.96M | -2.83M | -3.76M |
| EPS Basic | -0.15 | -0.23 | -0.12 | -0.16 | -0.22 |
| Normalized Basic EPS | -0.09 | -0.12 | -0.08 | -0.10 | -0.13 |
| EPS Diluted | -0.15 | -0.23 | -0.12 | -0.16 | -0.22 |
| Normalized Diluted EPS | -0.09 | -0.12 | -0.08 | -0.10 | -0.13 |
| Average Basic Shares Outstanding | 23.76M | 22.49M | 21.28M | 19.55M | 18.73M |
| Average Diluted Shares Outstanding | 23.76M | 22.49M | 21.28M | 19.55M | 18.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |